BAIWANG CO(06657): Wang Qiangyu Appointed as Co-General Manager
BAIWANG CO(06657) announced that, after considering the recommendation of the board's nomination committee, the board has resolved to appoint Mr. Wang Qiangyu as co-general manager of the Company, with his primary responsibilities being to coordinate the Group's AI product strategic planning and the technical optimization, product iteration, scenario adaptation and full-chain commercialization implementation of fiscal and tax large models, promote the deep application of artificial intelligence technology in the enterprise services field and business innovation, and help the Company build a competitive AI product system, effective from September 14, 2026.
BAIWANG CO(06657) announced that, after considering the recommendation of the board's nomination committee, the board has resolved to appoint Mr. Wang Qiangyu as co-general manager of the Company, with primary responsibilities for overseeing the Group's AI product strategic planning and the technical optimization, product iteration, scenario adaptation, and full-chain commercialization of fiscal and tax large models, promoting the deep application of artificial intelligence technology in the enterprise services sector and business innovation, and helping the Company build a competitive AI product system, effective from September 14, 2026.
Related Articles

AI risks and calls to "slow down" are heating up, and U.S. cybersecurity stocks are surging collectively.

"The first metaverse stock" bets on "AI-generated games"! Roblox (RBLX.US) competes for creator economy dividends, shares surge nearly 13%.
.png)
BIOHEART-B(02185) Enters into Strategic Cooperation Agreement with Shenqi Medical to Advance the Commercialization of the BIOHEART Bioresorbable Rapamycin-Eluting Coronary Stent System
AI risks and calls to "slow down" are heating up, and U.S. cybersecurity stocks are surging collectively.

"The first metaverse stock" bets on "AI-generated games"! Roblox (RBLX.US) competes for creator economy dividends, shares surge nearly 13%.

BIOHEART-B(02185) Enters into Strategic Cooperation Agreement with Shenqi Medical to Advance the Commercialization of the BIOHEART Bioresorbable Rapamycin-Eluting Coronary Stent System
.png)
RECOMMEND





